News
Do Gliflozins Affect the Need to Use Diuretics?
Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) have advanced from their initial role in reducing hyperglycemia in the treatment of type 2 diabetes mellitus (DM2) to antidiabetics with proven cardioprotective effects and additional indications for patients with heart failure or chronic kidney disease. Last year, the CHAMPION cohort study was published, which investigated the impact of empagliflozin use on diuretic prescribing and mid-term laboratory results in patients concurrently treated with diuretics.
INTERACTIVE CASE STUDY: Treatment of glaucoma medications without preservatives – current trend
The use of glaucoma medications without preservatives has been a trend in recent years. You can try…
Rapid Strengthening and Long-term Stabilization – New Strategy for Sequential Treatment of Severe Osteoporosis
Osteoanabolics have long been considered a treatment modality for osteoporosis that is only…
Inhibition of Sclerostin in Osteoporosis Therapy
Romosozumab, a subcutaneously administered antibody against sclerostin, is one of the most potent…
Doc. Tomáš Gabrhelík: Pain treatment should be seriously addressed by all fields, especially in seniors
Chronic pain is often underestimated, especially in older and polymorbid patients. On the other…
Three times on the topic of therapeutic cannabis usage possibilities – case studies from Czech practice
The following case studies from real Czech practice describe three cases of patients with various…
Ocrelizumab in the treatment of multiple sclerosis in real-world practice – a systematic review of published studies
In controlled study programs, ocrelizumab has demonstrated beneficial effects on improving clinical…
Innovation in Wound Healing: Zetuvit Plus Silicone Border for Optimal Wound Exudate Management
Excessive wound exudate can lead to delayed healing, skin damage around the wound, or leakage under…
Current Data of Tofacitinib in the Treatment of IBD: What Improvements in Endoscopic and Histologic Outcomes Can Be Achieved?
The oral Janus kinase inhibitor (JAKi) tofacitinib is currently approved for the treatment of…
Current News from ECCO 2023: Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Practice
At the 18th ECCO Congress, held in March 2023 in Copenhagen, results from a Spanish real-world…